Essential medicines and health products

WHO report suggests cost-effective approaches to access essential new medicines in Europe

26 March 2015 -- A new report on the affordability of new medicines in Europe shows that cooperation and transparency are the best tools to ensure equitable pricing and access. As the number of new medicines introduced in Europe rises, governments need novel policy approaches to evaluate the cost–effectiveness of new drugs and make informed public health choices.

Public consultation on emergency use assessment and listing procedures for medical products during public health emergencies

WHO Member States and all relevant stakeholders are invited to comment on the procedures until COB 10 April 2015.

Comments and suggestions will be evaluated and considered for possible inclusion in the current procedures if warranted. Final versions of the procedures will be made available on the WHO website after review.

WHO updates patent information on sofosbuvir and ledipasvir for the treatment of Hepatitic C Virus

World Hepatitis Alliance

New medicines on the market have given new hope to the millions of people who suffer from Hepatitis C Virus (HCV), a chronic disease that often leads to severe liver disease and kills between 350 000-500 000 people annually.
WHO works closely with Member State governments to assess and promote policy options for increasing access to these medicines, which remain unaffordable to many of those who need them and put an enormous financial strain even on the health systems of high-income countries.

Ebola vaccines, therapies, and diagnostics

Ebola specific prevention and treatment tools do not exist at the moment. In response to the severity and breadth of the current epidemic in West Africa, WHO has been spearheading efforts to galvanize the research and development of vaccines, treatments and diagnostics to curb the outbreak and ensure that these tools, if safe and effective, are also available for potential future outbreaks. To that end, WHO has convened the affected countries, donor and scientific communities, civil society and industry to gather the best evidence available and garner support for accelerated development and testing of the most promising tools. Two vaccines now being tested for safety could go into late phase trials in early 2015 and if results are positive they could be available to the affected populations by mid-next year.

News

Highlights